{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T13:55:52Z","timestamp":1694958952059},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2013,9,19]],"date-time":"2013-09-19T00:00:00Z","timestamp":1379548800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1007\/s00280-013-2295-6","type":"journal-article","created":{"date-parts":[[2013,9,18]],"date-time":"2013-09-18T12:34:01Z","timestamp":1379507641000},"page":"1073-1078","source":"Crossref","is-referenced-by-count":7,"title":["A phase I and pharmacokinetic study of oxaliplatin and bortezomib: activity, but dose-limiting neurotoxicity"],"prefix":"10.1007","volume":"72","author":[{"given":"B.","family":"Kobrinsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. O.","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Muggia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Liebes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Beric","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Malankar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Ivy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Hochster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,9,19]]},"reference":[{"issue":"11","key":"2295_CR1","first-page":"2615","volume":"59","author":"J Adams","year":"1999","unstructured":"Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59(11):2615\u20132622","journal-title":"Cancer Res"},{"issue":"3","key":"2295_CR2","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1200\/JCO.2005.11.030","volume":"23","author":"SV Rajkumar","year":"2005","unstructured":"Rajkumar SV, Richardson PG, Hideshima T, Anderson KC (2005) Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 23(3):630\u2013639. doi: 10.1200\/JCO.2005.11.030","journal-title":"J Clin Oncol"},{"issue":"4","key":"2295_CR3","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","volume":"23","author":"OA O\u2019Connor","year":"2005","unstructured":"O\u2019Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, Straus D, Portlock C, Hamlin P, Choi E, Dumetrescu O, Esseltine D, Trehu E, Adams J, Schenkein D, Zelenetz AD (2005) Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma. J Clin Oncol 23(4):676\u2013684. doi: 10.1200\/JCO.2005.02.050","journal-title":"J Clin Oncol"},{"issue":"25","key":"2295_CR4","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.1200\/JCO.2005.01.136","volume":"23","author":"AL Hamilton","year":"2005","unstructured":"Hamilton AL, Eder JP, Pavlick AC, Clark JW, Liebes L, Garcia-Carbonero R, Chachoua A, Ryan DP, Soma V, Farrell K, Kinchla N, Boyden J, Yee H, Zeleniuch-Jacquotte A, Wright J, Elliott P, Adams J, Muggia FM (2005) Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. J Clin Oncol 23(25):6107\u20136116. doi: 10.1200\/JCO.2005.01.136","journal-title":"J Clin Oncol"},{"issue":"2","key":"2295_CR5","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ygyno.2009.07.023","volume":"115","author":"C Aghajanian","year":"2009","unstructured":"Aghajanian C, Blessing JA, Darcy KM, Reid G, DeGeest K, Rubin SC, Mannel RS, Rotmensch J, Schilder RJ, Riordan W (2009) A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol 115(2):215\u2013220. doi: 10.1016\/j.ygyno.2009.07.023","journal-title":"Gynecol Oncol"},{"issue":"15","key":"2295_CR6","doi-asserted-by":"crossref","first-page":"5526","DOI":"10.1158\/1078-0432.CCR-05-0081","volume":"11","author":"H Mackay","year":"2005","unstructured":"Mackay H, Hedley D, Major P, Townsley C, Mackenzie M, Vincent M, Degendorfer P, Tsao MS, Nicklee T, Birle D, Wright J, Siu L, Moore M, Oza A (2005) A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. Clin Cancer Res 11(15):5526\u20135533. doi: 10.1158\/1078-0432.CCR-05-0081","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2295_CR7","first-page":"2323","volume":"60","author":"JC Cusack Jr","year":"2000","unstructured":"Cusack JC Jr, Liu R, Baldwin AS Jr (2000) Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothe cin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-kappaB activation. Cancer Res 60(9):2323\u20132330","journal-title":"Cancer Res"},{"issue":"6","key":"2295_CR8","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1124\/mol.109.063172","volume":"77","author":"SB Howell","year":"2010","unstructured":"Howell SB, Safaei R, Larson CA, Sailor MJ (2010) Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol Pharmacol 77(6):887\u2013894. doi: 10.1124\/mol.109.063172","journal-title":"Mol Pharmacol"},{"issue":"25","key":"2295_CR9","doi-asserted-by":"crossref","first-page":"5943","DOI":"10.1200\/JCO.2005.16.006","volume":"23","author":"C Aghajanian","year":"2005","unstructured":"Aghajanian C, Dizon DS, Sabbatini P, Raizer JJ, Dupont J, Spriggs DR (2005) Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer. J Clin Oncol 23(25):5943\u20135949. doi: 10.1200\/JCO.2005.16.006","journal-title":"J Clin Oncol"},{"issue":"1","key":"2295_CR10","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1345\/aph.1E319","volume":"39","author":"RJ Cersosimo","year":"2005","unstructured":"Cersosimo RJ (2005) Oxaliplatin-associated neuropathy: a review. Ann Pharmacother 39(1):128\u2013135. doi: 10.1345\/aph.1E319","journal-title":"Ann Pharmacother"},{"issue":"5 Suppl 15","key":"2295_CR11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1053\/sonc.2002.35524","volume":"29","author":"J Cassidy","year":"2002","unstructured":"Cassidy J, Misset JL (2002) Oxaliplatin-related side effects: characteristics and management. Semin Oncol 29(5 Suppl 15):11\u201320. doi: 10.1053\/sonc.2002.35524","journal-title":"Semin Oncol"},{"issue":"2","key":"2295_CR12","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.critrevonc.2006.01.001","volume":"59","author":"LM Pasetto","year":"2006","unstructured":"Pasetto LM, D\u2019Andrea MR, Rossi E, Monfardini S (2006) Oxaliplatin-related neurotoxicity: how and why? Crit Rev Oncol Hematol 59(2):159\u2013168. doi: 10.1016\/j.critrevonc.2006.01.001","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12 Pt 1","key":"2295_CR13","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1158\/1078-0432.CCR-03-0666","volume":"10","author":"L Gamelin","year":"2004","unstructured":"Gamelin L, Boisdron-Celle M, Delva R, Guerin-Meyer V, Ifrah N, Morel A, Gamelin E (2004) Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 10(12 Pt 1):4055\u20134061. doi: 10.1158\/1078-0432.CCR-03-0666","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2295_CR14","first-page":"579","volume":"34","author":"O Muto","year":"2007","unstructured":"Muto O, Ando H, Ono T, Itagaki H, Kobayashi Y, Onuki M, Akashi T, Tanaka Y, Hanaoka T (2007) Reduction of oxaliplatin-related neurotoxicity by calcium and magnesium infusions. Gan to kagaku ryoho Cancer Chemother 34(4):579\u2013581","journal-title":"Gan to kagaku ryoho Cancer Chemother"},{"issue":"4","key":"2295_CR15","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/1097-0142(19920215)69:4<893::AID-CNCR2820690410>3.0.CO;2-X","volume":"69","author":"F Levi","year":"1992","unstructured":"Levi F, Misset JL, Brienza S, Adam R, Metzger G, Itzakhi M, Caussanel JP, Kunstlinger F, Lecouturier S, Descorps-Declere A et al (1992) A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer 69(4):893\u2013900","journal-title":"Cancer"},{"issue":"10","key":"2295_CR16","first-page":"3493","volume":"31","author":"AL Kautio","year":"2011","unstructured":"Kautio AL, Haanpaa M, Kautiainen H, Leminen A, Kalso E, Saarto T (2011) Oxaliplatin scale and National Cancer Institute-Common Toxicity Criteria in the assessment of chemotherapy-induced peripheral neuropathy. Anticancer Res 31(10):3493\u20133496","journal-title":"Anticancer Res"},{"issue":"3","key":"2295_CR17","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205\u2013216","journal-title":"J Natl Cancer Inst"},{"issue":"1\u20132","key":"2295_CR18","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0162-0134(99)00135-X","volume":"77","author":"D Screnci","year":"1999","unstructured":"Screnci D, McKeage MJ (1999) Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches. J Inorg Biochem 77(1\u20132):105\u2013110","journal-title":"J Inorg Biochem"},{"issue":"1","key":"2295_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/COC.0b013e31805c142f","volume":"31","author":"SJ Cohen","year":"2008","unstructured":"Cohen SJ, Engstrom PF, Lewis NL, Langer CJ, McLaughlin S, Beard M, Weiner LM, Meropol NJ (2008) Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors. Am J Clin Oncol 31(1):1\u20135. doi: 10.1097\/COC.0b013e31805c142f","journal-title":"Am J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2295-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-013-2295-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2295-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T10:11:32Z","timestamp":1559038292000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-013-2295-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,19]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["2295"],"URL":"https:\/\/doi.org\/10.1007\/s00280-013-2295-6","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,19]]}}}